We are live on ! Find out more
DCI

Data Collective IV Portfolio holdings

AUM $55.9M
1-Year Est. Return 49.14%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+49.14%
3 Year Est. Return
+250.98%
5 Year Est. Return
10 Year Est. Return
AUM
$121M
AUM Growth
+$15.2M
Cap. Flow
+$7
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
2
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Industrials 51.2%
2 Healthcare 48.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RXRX icon
1
Recursion Pharmaceuticals
RXRX
$1.62B
$58.6M 48.46%
5,941,120
EVLV icon
2
Evolv Technologies
EVLV
$1.01B
$45.7M 37.8%
9,681,281
+1
+0% +$4
RKLB icon
3
Rocket Lab Corp
RKLB
$39.9B
$16.2M 13.4%
2,929,350
DFTX
4
Definium Therapeutics
DFTX
$5.57B
$367K 0.3%
100,350
+1
+0% +$3
ROIV icon
5
Roivant Sciences
ROIV
$24.3B
$43.5K 0.04%
3,875

Similar funds

Data Collective IV's Q4 2023 Portfolio in Review

As of Q4 2023, Data Collective IV held 5 positions worth $121M, up 14% from $106M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2023: portfolio turnover was 0%. Data Collective IV opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Industrials at 51% of assets, down from 57% a quarter earlier, followed by Healthcare.

  • Data Collective IV added most to Evolv Technologies in Q4 2023, an estimated $4 increase.
  • Data Collective IV's ten largest holdings make up 100% of its $121M portfolio in Q4 2023.
  • Data Collective IV opened 0 new positions and closed 0 in Q4 2023.
  • Data Collective IV's portfolio value rose 14% quarter-over-quarter to $121M.

Based on Data Collective IV's 13F filing for Q4 2023, filed 14 Feb 2024.